The Setback of Halting Psychedelic Research in the 1970s for Science

“Before the 1970s’ war on drugs, there was a variety of promising research into therapeutic psychedelics.”

Adrià Voltà

In the early 1950s, notable figures in science, philosophy, culture, and politics—such as Albert Einstein, Carl Jung, and Graham Greene—were part of an initiative called “outsights” aimed at exploring powerful psychedelics. Although circumstances shifted, I find myself captivated by what could have been.

I’ve been delving into psychedelics in the new trip series on BBC Radio 4. I previously shared my experiences of vivid hallucinations while in a coma from Covid-19. This sparked my curiosity to understand why individuals actively pursue psychedelic experiences, navigate legal challenges, take risks at home, seek healing, and address unmet needs.

There has yet to be a global consensus banning psychedelics. Responding to inquiries by scientist Humphrey Davy, who researched suboxidized oxides in 1799, Humphrey Osmond, coining the term psychedelic in the 1950s, expressed that the study of chemically induced altered states merits rigorous and thoughtful research.

Before the U.S.-led drug war commenced in the 1970s, extensive and promising research into psychedelics as potential treatments was underway, alongside their longstanding use in sacred and ritual contexts by Indigenous cultures. Unfortunately, rather than permitting this exploration, it was driven underground, leaving many to view substances such as fungi and plants, or their lab-created variants, as otherworldly. This otherness surprised me.

Currently, psychedelic research is investigating their therapeutic potential for conditions like depression, addiction, PTSD, eating disorders, dementia, and intergenerational trauma, gaining momentum globally. Studies explore their possible use in extending the recovery window following strokes, enhancing rehabilitation, and even unraveling the nature of consciousness.

Conversations with researchers who meticulously examine substances like psilocybin and DMT in clinical environments feel worlds apart from the psychedelic narratives prevalent in popular culture. These molecules profoundly and enduringly influence our minds and perceptions. It’s perplexing how we opted to stifle a broader inquiry and obstruct our brightest minds from discovering their true potential.

Today’s discussions among researchers are as engaging as they come, yet I can’t help but linger on the “what if?” In light of the global mental health crisis, governments and health systems are eager for new treatment alternatives. Public funding is dwindling and faces threats in many areas, while large corporations driven by profit show substantial interest in the accessibility of new therapies. Changes are happening rapidly.

Examining humanity’s history with psychedelic substances reveals a narrative marked by significant self-inflicted wounds. Ultimately, the funds for the outsight initiative never materialized, leading to a drastically different chapter in history. The war on drugs has stalled research across numerous substances for decades and continues to cast a shadow today.

The narratives surrounding these substances serve as warnings. Politics should never obstruct scientific breakthroughs. In light of today’s world, it feels like an urgent moral imperative to safeguard and nurture the conditions necessary for science to thrive. The stakes are too high.

Source: www.newscientist.com

Halting Submissions: The Impact of NIH Budget Cuts on Scientific Journals

The Environmental Health Perspective is widely regarded as the premier magazine in the field, announcing its suspension of new research submissions due to uncertainties surrounding federal funding cuts.

For over 50 years, this journal has been supported by the National Institutes of Health to evaluate research on the impacts of environmental toxins, including persistent chemicals and air pollution, publishing findings at no cost.

Joel Kaufman, the journal’s editor-in-chief, opted to halt new submissions because of the “lack of confidence” regarding the funding of critical expenses such as copyediting and updating editing software.

He refrained from providing comments on the publication’s future outlook.

“If the journal were to disappear, it would be a tremendous loss,” stated Jonathan Levy, Chair of the Department of Environmental Health at Boston University. “It diminishes access to crucial information needed for insightful decision-making.”

The NEJM editor referred to the letter as “blushy threats.” Recently, the journal Obstetrics and Gynecology, published by the American College of Obstetricians and Gynecologists, reported receiving similar letters.

Scientific journals have been under scrutiny from leading health officials during the Trump administration.

In a book published last year, Dr. Martin A. McCurry, the newly appointed FDA commissioner, indicated that the Editorial Committee of “Gatekeeping” will only disseminate information that aligns with “groupthink narratives.”

In an interview from last year’s “Dr. Hyman Show” podcast, current HHS Secretary Robert F. Kennedy Jr. expressed intentions to take legal action against medical journals under the Federal Anti-Corruption Act.

“If you don’t establish a plan to publish credible science now, I will find a way to sue you,” he warned.

Still, the uncertainty surrounding EHP has left researchers perplexed. They noted that funding cuts seem to conflict with the Trump administration’s declared priorities.

For instance, Kennedy has consistently highlighted the significance of investigating environmental factors in chronic diseases. The new administration has also shown interest in transparency and public access to scientific journals, a principle EHP pioneered.

EHP was among the first “open access” journals, accessible to anyone without a subscription, and unlike many other open access journals that impose substantial fees, EHP’s federal backing allowed researchers at smaller institutions to publish without financial concerns.

“There are several layers of irony in this situation,” Dr. Levy remarked.

EHP isn’t the only journal affected by funding cuts at the Department of Health and Human Services.

A draft budget obtained by The New York Times suggests that two journals published by the CDC—Emerging Infectious Diseases and Chronic Diseases—may face cuts. Both are available at no cost to authors and readers and are among the leading journals in their fields.

HHS spokesman Andrew Nixon stated that there was “no final decision” on the forthcoming budget.

Published monthly, Emerging Infectious Diseases provides state-of-the-art insights on global infectious disease threats.

Jason Kindrachuk, a virologist at the University of Manitoba, who has published studies on Marburg and MPOX in the journal, noted its importance in shaping response strategies during outbreaks.

The news is “very disheartening,” he remarked.

Source: www.nytimes.com